Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
October 29, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019

Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
August 08, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
April 26, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Axsome...
March 12, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics

NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
March 17, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

First Patient Enrolled in the STRIDE-1 Study Second Product Candidate Axsome Has Advanced into a Pivotal Trial NEW YORK, March 17, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc....